Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide technologies, services and the critical information needed to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company was formed in 1996 to develop and market the ACIS® Automated Cellular Imaging System, an important advance in slide-based testing. The rise of individualized medicine as the new direction in oncology led the company in 2004 to expand its business model to provide a full range of leading diagnostic technologies such as flow cytometry and molecular testing in-house, creating a state-of-the-art commercial cancer laboratory and providing advanced oncology testing and drug development services. For more information about Clarient, please visit its website at www.clarientinc.com.

Contact Information

31 Columbia
Aliso Viejo, CA 92656

tel: 949-425-5700
fax: 949-425-5701


Investor Relations



Exchange: NASDAQ
Industry: Scientific & Technical Instruments
Market Cap: $142.7M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.